In the world of modern healthcare, there’s a new term that’s creating waves: Diabesity. Coined to capture the dual epidemic of diabetes and obesity, diabesity highlights how these two chronic conditions often go hand-in-hand—and how addressing them together may hold the key to better health outcomes. Diabesity: A Global Health Crisis Let’s break it down: … Read more
Retatrutide is a promising experimental weight loss drug under development by Eli Lilly. Known as the “Triple G” drug, it mimics three hormones (GLP-1, GIP, and glucagon) to promote significant weight loss. Early studies show it outperforms existing FDA-approved drugs like Ozempic, helping patients lose up to 22% of their weight in 48 weeks. Retatrutide … Read more
Liver disease, especially metabolic dysfunction-associated steatohepatitis (MASH), has long been a silent threat, affecting millions of people globally. Often progressing unnoticed until advanced stages, MASH—formerly known as nonalcoholic steatohepatitis (NASH)—can lead to liver fibrosis, cirrhosis, and even liver failure. For years, patients and physicians alike have faced a harsh reality: there are virtually no approved … Read more
GLORY-1 is an innovative investigational therapy in the field of metabolic health, designed as a dual receptor agonist targeting both glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptors. Developed by Innovent Biologics, GLORY-1—also known by its research name, Mazdutide—aims to deliver superior efficacy for weight loss and metabolic improvements by combining the actions of these two … Read more
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been published in The New England Journal of Medicine (NEJM), signaling a pivotal advancement in the fight against obesity. The trial, known as GLORY-1, demonstrates the remarkable efficacy and safety of mazdutide in Chinese adults with … Read more
The global obesity drug market is experiencing significant growth, with projections exceeding $150 billion annually in the coming decade. This surge is driven by the development and success of GLP-1 receptor agonists and related therapies. Here’s an analysis of key publicly traded companies leading this sector: 1. Eli Lilly & Co. (NYSE: LLY) 2. Novo … Read more
Key Findings at a Glance The Study: How Weight-Loss Drugs Stack Up Against Surgery A landmark Israeli study (presented at the European Congress on Obesity 2025 and published in The Lancet’s eClinicalMedicine) analyzed 6,000 adults with obesity but no prior cancer. Two Groups Compared: Surprising Results Lead author Prof. Dror Dicker (Israel):“Newer GLP-1 drugs like Mounjaro may be even more powerful … Read more
